Home » Stocks » Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. (ADMS)

Stock Price: $3.78 USD 1.17 (44.83%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.89 +0.11 (2.91%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 106.44M
Revenue (ttm) 57.45M
Net Income (ttm) -77.87M
Shares Out 28.16M
EPS (ttm) -3.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.78
Previous Close $2.61
Change ($) 1.17
Change (%) 44.83%
Day's Open 3.20
Day's Range 3.19 - 4.14
Day's Volume 5,946,311
52-Week Range 1.90 - 7.78

More Stats

Market Cap 106.44M
Enterprise Value 139.92M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.16M
Float 20.33M
EPS (basic) -2.78
EPS (diluted) -3.31
FCF / Share -2.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 931,410
Short Ratio 1.56
Short % of Float 3.06%
Beta 1.77
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.85
PB Ratio n/a
Revenue 57.45M
Operating Income -64.20M
Net Income -77.87M
Free Cash Flow -66.50M
Net Cash -33.48M
Net Cash / Share -1.19
Gross Margin 90.80%
Operating Margin -111.74%
Profit Margin -122.50%
FCF Margin -115.75%
ROA -26.12%
ROE -383.56%
ROIC -29.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 7
Overweight 0
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(142.59% upside)
Current: $3.78
Target: 9.17
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth60.48%5862.52%-0.17%-70.15%-96.57%-21.45%89.73%-
Gross Profit52.1733.410.550.571.9255.8571.1037.47
Operating Income-92.24-115-87.93-60.98-57.4418.5157.0219.95
Net Income-105-131-89.49-60.06-51.808.9733.0711.44
Shares Outstanding27.6826.8922.5621.7118.1114.849.519.49
Earnings Per Share-3.80-4.87-3.97-2.77-2.860.532.991.17
EPS Growth------82.27%155.56%-
Operating Cash Flow-80.78-104-66.83-48.07-47.2127.7926.8051.96
Capital Expenditures-0.02-1.06-1.26-1.62-1.40-1.29-0.17-0.02
Free Cash Flow-80.80-105-68.09-49.69-48.6126.5126.6351.94
Cash & Equivalents13321117311410712285.6162.96
Total Debt136119103----4.00
Net Cash / Debt-3.3891.7570.8011410712285.6158.96
Book Value-0.8989.8966.1313211614756.614.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adamas Pharmaceuticals, Inc.
Country United States
Employees 136
CEO Neil F. McFarlane

Stock Information

Ticker Symbol ADMS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ADMS
IPO Date April 10, 2014


Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.